mesoporous silica nanoparticle
Recently Published Documents


TOTAL DOCUMENTS

252
(FIVE YEARS 81)

H-INDEX

44
(FIVE YEARS 8)

Pharmaceutics ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 56
Author(s):  
Achraf Noureddine ◽  
Michael L. Paffett ◽  
Stefan Franco ◽  
Alfonso E. Chan ◽  
Sandeep Pallikkuth ◽  
...  

This study examines intra- and intercellular trafficking of mesoporous silica nanoparticles along microtubular highways, with an emphasis on intercellular bridges connecting interphase and telophase cells. The study of nanoparticle trafficking within and between cells during all phases of the cell cycle is relevant to payload destination and dilution, and impacts delivery of therapeutic or diagnostic agents. Super-resolution stochastic optical reconstruction and sub-airy unit image acquisition, the latter combined with Huygens deconvolution microscopy, enable single nanoparticle and microtubule resolution. Combined structural and functional data provide enhanced details on biological processes, with an example of mitotic inheritance during cancer cell trivision.


2021 ◽  
pp. 2100125
Author(s):  
Melanie Gerstenberg ◽  
Christina M. Stürzel ◽  
Tanja Weil ◽  
Frank Kirchhoff ◽  
Mika Lindén

Author(s):  
Han Wu ◽  
Xin-Fei Xu ◽  
Jia-Qi Zhu ◽  
Ming-Da Wang ◽  
Chao Li ◽  
...  

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)–based cytotoxic or immunoregulatory drug–loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.


Sign in / Sign up

Export Citation Format

Share Document